Based in Doylestown, PA, Atrin Pharmaceuticals is focused on discovering and developing innovative treatments for cancer. Their most advanced program is centered around a new class of compounds that specifically inhibit ATR, a key mediator of DNA repair. Using their proprietary, human cell-based, high-throughput screening platform, Atrize™, the company is assembling a pipeline of additional drug candidates that are effective in inhibiting cancer cell viability without adversely affecting healthy cells. Atrin's anticancer therapeutic drugs are designed to treat a broad spectrum of cancers associated with synthetic lethality and the deregulated DNA damage response. These drugs are hyperactive in cancer cells, perform a vital function without which the cancer cells could be destroyed, and create a molecule that causes the collapse of replication forks, enabling patients to get unusual, effective, and safe drugs for the treatment of cancer.